drugset / Trial / NCT01373294
Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer
Phase 2
Completed
17 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Celgene Corporation · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purposes of this study are to: * find out whether participants' cancer returns or gets worse while they are taking lenalidomide and Bacille Calmette-Guerrin (BCG); * evaluate the safety and tolerability of the combination of lenalidomide and BCG; * compare the cancer progression of participants taking lenalidomide and BCG versus participants taking only BCG
Timeline
- Start
- 2011-11-30
- Primary completion
- 2015-01-09
- Completion
- 2018-12-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bacille Calmette-Guerrin | Vaccine | — | Intravenous |
| Subject | Lenalidomide | Other / unclassified | 10 mg | Oral |